CCDC 822185: Experimental Crystal Structure Determination
Antonia F. Stepan(Pfizer (United States)), R. Scott Obach(Pfizer (United States)), David Riddell(Eli Lilly (United States)), T.J. O'Sullivan, Sven Becker(Laboratoire National Henri Becquerel), Christopher J. O’Donnell(Pfizer (United States)), P.H. Dorff, Leslie R. Pustilnik(Pfizer (United States)), Chakrapani Subramanyam(Pfizer (United States)), Kenneth J. DiRico(Pfizer (United States)), S.H. Capetta(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Khadga Jung Karki, Brian T. Sneed, Walter S. McDonald, C.E. Nolan, Hao Sun, A. B. Wood, Ivan Efremov(Pfizer (United States)), Amy Won, EDWARD MILLER, Yasong Lu(Pfizer (United States)), A.J. Hallgren(Pfizer (United States)), J.K. Dutra, E. Sibley(Pfizer (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302